focus
WASHINGTON — Senators on the Finance Committee on Wednesday nearly unanimously passed a bill to clamp down on drug middlemen, but kicked the can down the road on some of the more challenging policies.
The bill would offer some more transparency into the business practices of pharmacy benefit managers, ensure PBMs aren’t skimming off of the money they send to insurers, prohibit them from overcharging insurers, and ensure certain fees in the Medicare program aren’t tied to a drug’s price.
advertisement
“It’s pretty hard to get 26 votes around here,” Finance Chair Ron Wyden (D-Ore.) said after the vote. “So we’re thrilled.”
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
IVG is promising — but it won’t replace IVF quite yet
Next article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The cancer drug shortage isn’t new — and neither are the solutions
